UPCOMING EVENTS

NEWS

St. Louis synthetic blood startup raises $800,000

St. Louis Business Journal By Brian Robbins June 4, 2018, 2:41 pm A biotech startup that is developing bio-synthetic hybrid red blood cells has raised $800,000 from investors, according to a Securities and Exchange Commission filing. KaloCyte Inc., founded in 2016 and...

read more

Wash U continues quest to develop artificial blood

By Shahla Farzan Apr 13, 2018 Thousands of people in the United States die each year due to severe blood loss, often before they reach an emergency room. To help reduce the number of trauma deaths, a Washington University research team is working to develop an...

read more

$5 million aids development of artificial red blood cells

Research focused on preventing deaths from traumatic bleeding Washington University in St. Louis By Kristina Sauerwein  February 27, 2018 Trauma is the leading cause of death for Americans under the age of 46. In the U.S., there are about 30,000 preventable deaths...

read more

Erythromer, a nanoscale bio-synthetic artificial red cell

VJHemOnc Video Journal of Hematological Oncology Published on Dec 16, 2016 Press brief by Allan Doctor, MD of Washington University School of Medicine, St. Louis, MO, on erythromer (EM), a nanoscale bio-synthetic artificial red cell: proof of concept and In vivo...

read more

Bioengineering: Doing without donors | Nature

Featured in NATURE 28 SEPTEMBER 2017 | VOL 549 | NATURE Each year, at about 13,000 collection centres worldwide, phlebotomists stick needles in the veins of healthy volunteers and amass in excess of 110 million donations of blood. The volume collected is enough to...

read more

CONTACT US

info@kalocyte.com

KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300 
Baltimore, MD 21201

ABOUT US

KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.